The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC).
 
Raphael Brandao Moreira
No Relationships to Disclose
 
Rana R. McKay
No Relationships to Disclose
 
Wanling Xie
No Relationships to Disclose
 
Daniel Yick Chin Heng
No Relationships to Disclose
 
Guillermo de Velasco
No Relationships to Disclose
 
Daniel E. Castellano
No Relationships to Disclose
 
Andre Poisl Fay
Honoraria - Astellas Pharma; Bristol-Myers Squibb; Novartis; Pfizer
Consulting or Advisory Role - Janssen-Cilag
Research Funding - CAPES-CNPq
 
Fabio Augusto Barros Schutz
No Relationships to Disclose
 
Connor Wells
No Relationships to Disclose
 
JoAnn Hsu
No Relationships to Disclose
 
Sumanta K. Pal
Honoraria - Astellas Pharma; Medivation; Novartis
Consulting or Advisory Role - Aveo; Bristol-Myers Squibb; Exelixis; Genentech; Myriad Pharmaceuticals; Novartis; Pfizer
Research Funding - Medivation
 
Jae-Lyun Lee
Honoraria - Astellas Pharma; Astellas Pharma; Pfizer
Consulting or Advisory Role - Astellas Pharma
Research Funding - Bayer; Exelixis; Janssen; Novartis; Pfizer
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Darren R. Feldman
Consulting or Advisory Role - Bayer; Gilead Sciences (I); Seagen
Research Funding - Novartis
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Pfizer; Prometheus; Roche/Genentech
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)